More needs to be done in renal cancer
Up to 90% of patients will die from metastatic disease and the search for biomarkers lags behind other tumour types, says ESMO Lifetime Achievement Award 2022 winner Prof. Bernard Escudier
More women in leadership roles are key to patient-centred medicine
According to this year’s ESMO Women for Oncology awardee Prof. Fatima Cardoso, steps forward in gender equality have been made, but progress is still slow
Can academic oncology compete with the career prospects offered by the pharma industry?
Moving back and forth across academic and corporate positions has become increasingly common for oncologists in search of new opportunities
Sibylle Loibl receives the ESMO Breast Cancer 2022 Award
In her Keynote Lecture at ESMO Breast Cancer 2022, Prof. Sibylle Loibl looks at neoadjuvant therapy and the fertility and pregnancy issues facing young women with breast cancer
Fred R. Hirsch receives the Heine H. Hansen Award 2022
In his Award Keynote Lecture at the European Lung Cancer Congress 2022, Prof. Fred R. Hirsch describes how ‘the tissue is still the issue’
Lesley Seymour receives the TAT Honorary Award 2022
In her keynote lecture at the ESMO Targeted Anticancer Therapies Congress 2022, Prof. Lesley Seymour stresses the importance of sharing ideas and resources between academia and industry
Quality cancer care starts with training oncologists at the highest standards
Despite the encouraging findings of a new global survey demonstrating a high rate of uptake of the ESMO/ASCO Global Curriculum in Medical Oncology, resource limitations in lower-income regions as well as country-specific political circumstances may be hindering its implementation locally.
Immunotherapy: from initial scepticism to the heart of cancer treatment
The ESMO Award for Immuno-Oncology 2021 is given to Prof. Wolf H. Fridman, whose research has made significant contributions to unveiling the prognostic and predictive role of the tumour microenvironment
How much is enough with immunotherapy?
For the recipient of the ESMO Award for Immuno-Oncology 2020, Dr Jedd Wolchok, one of the biggest challenges in the field is knowing how and when to de-escalate immunotherapy
Early and relapsed TNBC is no longer so negative
Research and treatment approaches have come a long way since triple-negative breast cancer was first recognised, but there is still progress to be made, according to Associate Prof. Rebecca Dent